Eli Lilly

Eli Lilly and Company is a global pharmaceutical leader headquartered in Indianapolis, Indiana, with a legacy spanning over 145 years. The company specializes in developing breakthrough treatments across core therapeutic areas including endocrinology, oncology, immunology, and neuroscience. Lilly is currently a market leader in the metabolic space with its blockbuster GLP-1/GIP receptor agonist tirzepatide and has a significant presence in Alzheimer's disease with donanemab. The company maintains a robust R&D pipeline and extensive global manufacturing capabilities for both small molecules and biologics. Through strategic acquisitions and internal innovation, Lilly continues to expand its portfolio into genetic medicines and radiopharmaceuticals.